Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Athira Pharma Inc (NQ: ATHA )

2.140 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.140
Bid (Size) 2.070 (2)
Ask (Size) 2.430 (3)
Prev. Close 2.140
Today's Range 2.140 - 2.140
52wk Range 1.330 - 4.298
Shares Outstanding 38,054,583
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Athira Pharma to Participate in Upcoming May Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercialization 
From Athira Pharma, Inc.
Via GlobeNewswire

Performance

YTD
-25.95%
-25.95%
1 Month
-11.57%
-11.57%
3 Month
-30.97%
-30.97%
6 Month
+42.67%
+42.67%
1 Year
-24.91%
-24.91%

More News

Read More
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
From Athira Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
From Athira Pharma, Inc.
Via GlobeNewswire
Sidoti Events, LLC's Virtual December Small-Cap Conference
Via ACCESSWIRE
These biotechs targeting multiple neurodegenerative diseases
Via MarketBeat
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Participate in Jefferies London Healthcare Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Participate in Upcoming October Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
How The Same Treatments May Work For Multiple Neurodegenerative Diseases
Via Talk Markets
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.